Development of novel peptide aldehyde based proteasome inhibitors as potential anti-cancer agents

825 words
Number of references should be 10-12
Please find the attached paper for your reference.

Introduction
20s proteasomes and cancer (ref – 1 to 4)
Novel proteasome inhibitors for anti-cancer drugs (Ref -5 and 6)
So far developed inhibitors including peptide inhibitors (ref – 7 to 11)
Other papers (ref 12 to 14)

1. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004. 5(5): p. 417-421.
2. Adams, J., The proteasome: A suitable antineoplastic target. Nature Reviews Cancer, 2004. 4(5): p. 349-360.
3. Nandi, D., et al., The ubiquitin-proteasome system. Journal of Biosciences, 2006. 31(1): p. 137-155.
4. Kisselev, A.F. and A.L. Goldberg, Proteasome inhibitors: from research tools to drug candidates. Chemistry & Biology, 2001. 8(8): p. 739-758.
5. Crawford, L.J., B. Walker, and A.E. Irvine, Proteasome inhibitors in cancer therapy. Journal of Cell Communication and Signaling, 2011. 5(2): p. 101-110.
6. Harer, S.L., M.S. Bhatia, and N.M. Bhatia, Proteasome inhibitors mechanism; source for design of newer therapeutic agents. Journal of Antibiotics, 2012. 65(6): p. 279-288.
7. Manasanch, E.E. and R.Z. Orlowski, Proteasome inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2017. 14(7): p. 417-433.
8. Chen, D., et al., Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Current Cancer Drug Targets, 2011. 11(3): p. 239-253.
9. Moreau, P., et al., Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 2012. 120(5): p. 947-959.
10. Infante, J.R., et al., A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investigational New Drugs, 2016. 34(2): p.

216-224.

1. Han, Y.H., et al., The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep, 2009. 22(1): p. 215-21.
2. Thompson, R.C., Peptide aldehydes: potent inhibitors of serine and cysteine proteases. Methods Enzymol, 1977. 46: p. 220-5.
3. Cassetta, L. and J.W. Pollard, Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov, 2018.
4. Zaal, E.A., et al., Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer & Metabolism, 2017. 5.